Sign In
Buy ATNM
$1.16
-0.0600 (-4.92%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal se
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
10:02am, Monday, 28'th Apr 2025
NEW YORK CITY, NY / ACCESS Newswire / April 28, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To
- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists foll
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML
May 27, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ATNM
05:45am, Monday, 28'th Apr 2025
NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM duri
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
10:25am, Saturday, 26'th Apr 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between Oc
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal se
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
02:35pm, Friday, 25'th Apr 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options NEW YORK
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal se
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM
Shareholders of Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
07:25am, Friday, 25'th Apr 2025
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESS Newswire / April 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actin
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact Levi & Korsinsky
05:45am, Friday, 25'th Apr 2025
NEW YORK , April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. C
